Aurora Cannabis (NASDAQ: ACB) launches U.S.$100M at-the-market share program

Rhea-AI Filing Summary

Aurora Cannabis Inc. established an at-the-market share offering program that permits it to issue and sell up to U.S.$100 million of common shares from treasury through U.S. markets over time at prevailing prices.

The company plans to use any net proceeds only for strategic and accretive purposes, including increasing cultivation capacity and pursuing mergers and acquisitions. Sales will occur on the NASDAQ or other U.S. marketplaces, or via privately negotiated transactions, under a sales agreement with TD Securities (USA) LLC and a filed prospectus supplement to its existing base shelf prospectus and Form F-10 registration statement.

Insights

Equity capital markets analyst

Aurora creates flexibility to raise up to U.S.$100 million via an at-the-market share program.

Aurora Cannabis has put in place an at-the-market (ATM) program allowing issuance and sale of up to U.S.$100 million of common shares from treasury through U.S. trading venues. Sales occur at prevailing market prices, giving management flexibility on timing and size.

The company states that net proceeds will be used only for strategic and accretive purposes, including increased cultivation capacity and mergers and acquisitions. Actual impact depends on how much of the program is used, at what prices, and the returns generated by those investments.

Distributions will be made under a sales agreement with TD Securities (USA) LLC, supported by a prospectus supplement to its Canadian base shelf and U.S. Form F-10 registration statement. Future disclosures will indicate if and when shares are sold under this program and the amounts raised.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File No. 001-38691

AURORA CANNABIS INC. (Translation of registrant's name into English)

2207 90B St. SW
Edmonton, Alberta T6X 1V8
Canada
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  ☐ Form 40-F  ☒

SUBMITTED HEREWITH

Exhibits		Description
99.1		News release dated February 4, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AURORA CANNABIS INC.

/s/ Miguel Martin

Miguel Martin
Chief Executive Officer

Date: February 4, 2026

Exhibit 99.1 

 

Aurora Cannabis Announces Filing of Prospectus Supplement for At-The-Market Offering Program

NASDAQ | TSX: ACB

EDMONTON, AB, Feb. 4, 2026 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has filed a prospectus supplement establishing a new at-the-market offering program (the "ATM Program") that allows the Company to issue and sell up to U.S.$100 million of common shares in the capital of the Company (the "Common Shares") from treasury to the public, from time to time, at the Company's discretion.

The Company intends to use the net proceeds from the Offering for strategic and accretive purposes only, including for increased cultivation capacity and M&A.

Any Common Share sales under the ATM Program will be made through "at-the-market distributions" as defined in National Instrument 44-102 – Shelf Distributions and sold through the NASDAQ Capital Market (the "NASDAQ") or another marketplace in the United States at the prevailing market price at the time of sale. Sales may also be made in privately negotiated transactions. No sales will be made through a stock exchange or stock market in Canada.

Distributions of the Common Shares through the ATM Program will be made pursuant to the terms of a sales agreement dated February 4, 2026 among the Company and TD Securities (USA) LLC.

A prospectus supplement (the "Prospectus Supplement") to the Company's short form base shelf prospectus dated February 14, 2025 (the "Base Shelf Prospectus") has been filed with the securities commissions or securities regulatory authorities in each of the provinces of Canada, except Quebec, and with the U.S. Securities and Exchange Commission (the "SEC") as part of the Company's registration statement on Form F-10 (the "Registration Statement") under the U.S./Canada Multijurisdictional Disclosure System. The Prospectus Supplement, the Base Shelf Prospectus and the Registration Statement contain important detailed information about the Company and the ATM Program. Prospective investors should read the Prospectus Supplement, the Base Shelf Prospectus and the Registration Statement and the other documents the Company has filed for more complete information about the Company and the ATM Offering before making an investment decision. Copies of the Prospectus Supplement and the Base Shelf Prospectus are available on SEDAR+ at www.sedarplus.ca and copies of the Prospectus Supplement and the Registration Statement will be available on EDGAR at www.sec.gov.

This news release does not constitute an offer to sell or the solicitation of an offer to buy the Common Shares, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aurora Cannabis

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora^®, MedReleaf^®, Pedanios^®, IndiMed™, San Raf^®, Tasty's™, and Whistler Cannabis Co.™. The company also holds a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.

Learn more at www.auroramj.com and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Information

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the timing and completion of the ATM Program and the expected use of proceeds of the ATM Program. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and nongovernment consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information form dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.ca and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-announces-filing-of-prospectus-supplement-for-at-the-market-offering-program-302678634.html

SOURCE Aurora Cannabis Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2026/04/c1800.html

%CIK: 0001683541

For further information: For Media: Michelle Lefler, VP, Communications & PR, media@auroramj.com; For Investors: ICR, Inc., aurora@icrinc.com

CO: Aurora Cannabis Inc.

CNW 07:00e 04-FEB-26

FAQ

What did Aurora Cannabis (ACB) announce in this 6-K filing?

Aurora Cannabis announced a new at-the-market share offering program allowing it to issue up to U.S.$100 million of common shares. Shares may be sold from treasury on U.S. marketplaces at prevailing prices, giving the company flexible access to additional equity capital over time.

How much can Aurora Cannabis (ACB) raise under its new at-the-market program?

Aurora Cannabis can issue and sell up to U.S.$100 million of common shares under the program. These shares will be sold from treasury through the NASDAQ Capital Market or other U.S. marketplaces, as well as in privately negotiated transactions, at market prices when sales occur.

How will Aurora Cannabis (ACB) use proceeds from the at-the-market offering?

Aurora Cannabis intends to use net proceeds only for strategic and accretive purposes. The company specifically highlights funding increased cultivation capacity and mergers and acquisitions, indicating a focus on growth initiatives rather than general corporate purposes or routine operating expenses.

Where will Aurora Cannabis (ACB) shares be sold under the at-the-market program?

Shares under the program will be sold on U.S. marketplaces, primarily the NASDAQ Capital Market. The company notes that no sales will occur through Canadian stock exchanges, though privately negotiated transactions in the United States may also be used alongside exchange-based sales.

Which documents govern Aurora Cannabis (ACB)'s at-the-market offering program?

The program is governed by a prospectus supplement to Aurora’s short form base shelf prospectus and its Form F-10 registration statement. These documents, filed in Canada and with the U.S. SEC, provide detailed information about the company and the offering framework.

Who is Aurora Cannabis (ACB)'s sales agent for the at-the-market program?

TD Securities (USA) LLC acts as sales agent under a sales agreement dated February 4, 2026. Distributions of common shares through the at-the-market program will be made pursuant to this agreement, which sets out the mechanics for placing shares into the U.S. market.